Papers - YAMAMOTO Hayato
-
Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study.
Kubota Y, Hatakeyama S, Tanaka T, Fujita N, Iwamura H, Mikami J, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Sasaki A, Kawaguchi T, Ohyama C
Oncotarget 8 ( 60 ) 101500 - 101508 2017.11
-
Incidental prostate cancer in patients with muscle-invasive bladder cancer who underwent radical cystoprostatectomy.
Toshikazu Tanaka, Takuya Koie, Chikara Ohyama, Yasuhiro Hashimoto, Atsushi Imai, Yuki Tobisawa, Shingo Hatakeyama, Hayato Yamamoto, Tohru Yoneyama, Hirotaka Horiguchi, Hirotake Kodama, Takahiro Yoneyama
Japanese journal of clinical oncology 47 ( 11 ) 1078 - 1082 2017.11
-
Incidental prostate cancer in patients with muscle-invasive bladder cancer who underwent radical cystoprostatectomy.
Tanaka T, Koie T, Ohyama C, Hashimoto Y, Imai A, Tobisawa Y, Hatakeyama S, Yamamoto H, Yoneyama T, Horiguchi H, Kodama H, Yoneyama T
Japanese journal of clinical oncology 47 ( 11 ) 1078 - 1082 2017.11
-
Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study.
Go Anan, Shingo Hatakeyama, Naoki Fujita, Hiromichi Iwamura, Toshikazu Tanaka, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Toshiaki Kawaguchi, Makoto Sato, Chikara Ohyama
Oncotarget 8 ( 49 ) 86130 - 86142 2017.10
-
Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study.
Anan G, Hatakeyama S, Fujita N, Iwamura H, Tanaka T, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Kawaguchi T, Sato M, Ohyama C
Oncotarget 8 ( 49 ) 86130 - 86142 2017.10
-
Preoperative chronic kidney disease predicts poor oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma.
Hirotake Kodama, Shingo Hatakeyama, Naoki Fujita, Hiromichi Iwamura, Go Anan, Ken Fukushi, Takuma Narita, Toshikazu Tanaka, Yuka Kubota, Hirotaka Horiguchi, Masaki Momota, Koichi Kido, Teppei Matsumoto, Osamu Soma, Itsuto Hamano, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Atsushi Sasaki, Toshiaki Kawaguchi, Makoto Sato, Chikara Ohyama
Oncotarget 8 ( 47 ) 83183 - 83194 2017.10
-
Preoperative chronic kidney disease predicts poor oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma.
Kodama H, Hatakeyama S, Fujita N, Iwamura H, Anan G, Fukushi K, Narita T, Tanaka T, Kubota Y, Horiguchi H, Momota M, Kido K, Matsumoto T, Soma O, Hamano I, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Sasaki A, Kawaguchi T, Sato M, Ohyama C
Oncotarget 8 ( 47 ) 83183 - 83194 2017.10
-
Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer.
Itsuto Hamano, Shingo Hatakeyama, Hiromichi Iwamurau, Naoki Fujita, Ken Fukushi, Takuma Narita, Kazuhisa Hagiwara, Ayumu Kusaka, Shogo Hosogoe, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Toshiaki Kawaguchi, Chikara Ohyama
Oncotarget 8 ( 37 ) 61404 - 61414 2017.9
-
Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer.
Hamano I, Hatakeyama S, Iwamurau H, Fujita N, Fukushi K, Narita T, Hagiwara K, Kusaka A, Hosogoe S, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Kawaguchi T, Ohyama C
Oncotarget 8 ( 37 ) 61404 - 61414 2017.9
-
Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.
Ayumu Kusaka, Shingo Hatakeyama, Shogo Hosogoe, Itsuto Hamano, Hiromichi Iwamura, Naoki Fujita, Ken Fukushi, Takuma Narita, Kazuhisa Hagiwara, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Toshiaki Kawaguchi, Chikara Ohyama
Oncotarget 8 ( 39 ) 65492 - 65505 2017.9
-
Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.
Kusaka A, Hatakeyama S, Hosogoe S, Hamano I, Iwamura H, Fujita N, Fukushi K, Narita T, Hagiwara K, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Kawaguchi T, Ohyama C
Oncotarget 8 ( 39 ) 65492 - 65505 2017.9
-
Presence of transient hydronephrosis immediately after surgery has a limited influence on renal function 1 year after ileal neobladder construction.
Takuma Narita, Shingo Hatakeyama, Takuya Koie, Shogo Hosogoe, Teppei Matsumoto, Osamu Soma, Hayato Yamamoto, Tohru Yoneyama, Yuki Tobisawa, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama
BMC urology 17 ( 1 ) 72 - 72 2017.8
-
Presence of transient hydronephrosis immediately after surgery has a limited influence on renal function 1 year after ileal neobladder construction.
Narita T, Hatakeyama S, Koie T, Hosogoe S, Matsumoto T, Soma O, Yamamoto H, Yoneyama T, Tobisawa Y, Yoneyama T, Hashimoto Y, Ohyama C
BMC urology 17 ( 1 ) 72 2017.8
-
Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma.
Shogo Hosogoe, Shingo Hatakeyama, Ayumu Kusaka, Itsuto Hamano, Yoshimi Tanaka, Kazuhisa Hagiwara, Hideaki Hirai, Satoko Morohashi, Hiroshi Kijima, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama
Oncotarget 8 ( 30 ) 49749 - 49756 2017.7
-
Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma.
Hosogoe S, Hatakeyama S, Kusaka A, Hamano I, Tanaka Y, Hagiwara K, Hirai H, Morohashi S, Kijima H, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ohyama C
Oncotarget 8 ( 30 ) 49749 - 49756 2017.7
-
A mammalian homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after cell-surface hyaluronidase.
Hayato Yamamoto, Yuki Tobisawa, Toshihiro Inubushi, Fumitoshi Irie, Chikara Ohyama, Yu Yamaguchi
The Journal of biological chemistry 292 ( 18 ) 7304 - 7313 2017.5
-
A mammalian homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after cell-surface hyaluronidase.
Yamamoto H, Tobisawa Y, Inubushi T, Irie F, Ohyama C, Yamaguchi Y
The Journal of biological chemistry 292 ( 18 ) 7304 - 7313 2017.5
-
Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer.
Ayumu Kusaka, Shingo Hatakeyama, Shogo Hosogoe, Itsuto Hamano, Hiromichi Iwamura, Naoki Fujita, Ken Fukushi, Takuma Narita, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Toshiaki Kawaguchi, Chikara Ohyama
Medical oncology (Northwood, London, England) 34 ( 5 ) 90 - 90 2017.5
-
Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma.
Ken Fukushi, Takuma Narita, Shingo Hatakeyama, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama
International journal of urology : official journal of the Japanese Urological Association 24 ( 5 ) 361 - 366 2017.5
-
Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.
Kazuhisa Hagiwara, Takuya Koie, Chikara Ohyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Yuki Tobisawa, Tohru Yoneyama
International urology and nephrology 49 ( 5 ) 811 - 816 2017.5